SLC5A2 and type 2 diabetes mellitus: Thus, SGLT2 inhibitors have beneficial effects on cardiovascular outcomes beyond their glucose-lowering action [4], and are now recommended to improve the prognosis of patients with type 2 diabetes and associated risk factors [5, 6].